How invasive cervical cancer audit affects clinical practice
|
|
- Francine Mason
- 6 years ago
- Views:
Transcription
1 How invasive cervical cancer audit affects clinical practice Referring to NHSCSP and EU guidelines and audits in Southampton and London Amanda Herbert Guy s & St Thomas Foundation NHS Trust
2 How invasive cervical cancer audit affects clinical practice Referring to NHSCSP and EU guidelines and audits in Southampton and London Amanda Herbert Guy s & St Thomas Foundation NHS Trust
3 What is the importance of invasive cervical cancer audit? Identifies areas where screening procedures could be improved Provides information to women about why their cancers were not prevented Provides information about the effectiveness and limitations of screening Demonstrates the importance of quality assurance guidelines (EU and NHSCSP)
4 NHSCSP guidelines for cervical cancer audit sp28.html (first document and changes for )
5 Aims and objectives of NHSCSP invasive cervical cancer audit
6 Co-ordinated by hospital-based programme co-ordinator (HBPC) who may be a cytopathologist gynaecologist or senior cytotechnologist HBPC works with lead consultants in cytopathology, gynaecological histopathology and colposcopy (and GPs) Overseen by Quality Assurance Reference Centre (QARC) and Screening Commissioner
7 NHSCSP update (mainly concerns slide reviews) Conventional smears need not be reviewed (conversion to LBC completed in 2008) Cytology slides within 5 years should be reviewed internally (previously within 10 years); excluding positive tests leading to diagnosis (with report provided to QARC) External (QARC) review of all negative and inadequate smears reported within 2 years; and any that were upgraded on internal review to high-grade All histology biopsies taken within 10 years before the diagnostic biopsy should be reviewed by a pathologist who did not report the slide; external review for discrepancies that would have altered management
8 NHSCSP update (mainly concerns slide reviews) Conventional smears need not be reviewed (conversion to LBC completed in 2008) Cytology slides within 5 years should be reviewed internally (previously within 10 years); excluding positive tests leading to diagnosis (with report provided to QARC) External (QARC) review of all negative and inadequate smears reported within 2 years; and any that were upgraded on internal review to high-grade All histology biopsies taken within 10 years before the diagnostic biopsy should be reviewed by a pathologist who did not report the slide; external review for discrepancies that would have altered management Castanon et al. Review of cytology and histopathology as part of the NHS Cervical Screening Programme audit of invasive cervical cancers. Cytopathology 2012;23:13-22.
9 European Guidelines for Quality Assurance in Cervical Cancer Screening 2008 PDFs can be downloaded FREE Wiener H et al. European guidelines for quality assurance in cervical cancer screening: cytology laboratories. Cytopathology 2007;18: Arbyn M et al. European guidelines for quality assurance in cervical cancer screening: recommendations for collecting samples for conventional and liquid-based cytology. Cytopathology 2007;18: Herbert A et al. European guidelines for quality assurance in cervical cancer screening: recommendations for cervical cytology terminology. Cytopathology 2007;18:213-9.
10 Can invasive cancer audit show where and why these guidelines matter? Rescreening of smears from patients with negative or low-grade test results less than 3-5 years before the diagnosis of invasive cancer forms an important part of quality control but should be taken in the context of all components of the screening history including cytological screening errors, sampling errors, noncompliance with follow-up recommendations, incomplete treatment and whether or not the cancer was screen-detected EU guidelines, 2nd edition 2008
11 Can invasive cancer audit show where and why these guidelines matter? References National audits (UK, NZ, Sweden [Andrae et al. J Natl Cancer Inst 2008; BMJ 2012; Silfverdal et al. Am J Obstet Gynecol 2009], Finland, Norway, Slovenia) Southampton & south west Hampshire (382 cancers BJOG 2009;116: & ) Guy s & St Thomas (133 cancers BJOG 2010; 117(6): Many women (up to 50%) with cancer have previously been screened. Why? Could these cancers have been avoided? If not, why not?
12 Results of Southampton audit (before during and after the introduction of organised screening and improved QA ) Significant trend towards screen-detected cancers in previously screened women (cytology within 5 years of diagnosis) as organised screening and improved QC became established ( ; ; ; ) Incidence fell from 16.8 to 10.4/100,000 women (in line with England as a whole) Strong association between screen-detected cancers, early FIGO stage, younger age groups and interval cancers
13 Trends in cancers according to screening history Southampton and south west Hampshire
14 Incidence per 100,000 eligible women aged screened and not screened within five years Screened within 5yrs Not screened within 5yrs
15 Effect of organised cervical screening in England 1971, 1986, and 2010 (40 years) Office for National Statistics data (n) = incidence in Cancer incidence per 100,000 women in each age band year per total 100,000 Screening women aged years started in ca in situ 4000 cancers 5-year age bands
16 Effect of organised cervical screening in England 1971, 1986, and 2010 (40 years) Office for National Statistics data Cancer incidence per 100,000 women in each age band (n) = incidence in year per total 100,000 Cancers, deaths and CIS/CIN3 increased x2, x2 and x3 in young women Increased screening coverage and risk (Peto 2004) 5-year age bands
17 Effect of organised cervical screening in England 1971, 1986, and 2010 (40 years) Office for National Statistics data Cancer incidence per 100,000 women in each age band (n) = incidence in year per total 100,000 NHSCSP launched in 1988 All women aged screened every 3-5 years 5-year age bands
18 Why do invasive cancers occur in populations with organised screening? Failure to screen the population at risk Irregular uptake and compliance False-negative cytology High-grade cytology reported as low-grade Failure to follow up low-grade cytology Delays or failures in referral of women recommended for colposcopy Treatment failures Some cancers are detected by cytology
19 Why do invasive cancers occur in populations with organised screening? Failure to screen the population at risk Irregular uptake and compliance False-negative cytology High-grade cytology reported as low-grade Failure to follow up low-grade cytology Delays or failures in referral of women recommended for colposcopy Treatment failures Many cancers (40-50%) are detected by cytology
20 Guy s & St Thomas Audit (133 cases) Screen-detected cancers were relatively more frequent in younger women (98.5% were either stage IA or IB1) Number of cancers in each age band Age band (years)
21 Guy s & St Thomas Audit (133 cases) Screen-detected cancers were relatively more frequent in younger women (98.5% were either stage IA or IB1) Number of cancers in each age band Age band (years)
22 Incidence of in-situ cervical carcinoma England 1980, 1990, 2000, 2010 (ONS data) Rates per 100,000 women in each age band (n) = rate in year per total 100,000 5-year age bands
23 Incidence of invasive cervical carcinoma England 1980, 1990, 2000, 2010 (ONS data) Rates per 100,000 women in each age band (n) = rate in year per total 100,000 Cancers = 3% of CIN3 + cancer at age year age bands
24 Reasons why cancers were not prevented Southampton (SSWH) and Guy s & St Thomas (GSTT)
25
26
27 Reasons why cancers were not prevented Southampton (SSWH) and Guy s & St Thomas (GSTT)
28 No previous cytology Southampton: 38.%; GSTT: 30.8% As screening becomes organised the percentage of cancers in women with no previous cytology declines (e.g. London vs. Southampton; Southampton over time) If every woman has been screened all cancers will be interval cancers 10% of women in England have no cytology test recorded on the central computer Many of these (in London at least) have been previously screened outside the UK Some are too young to have been offered screening within 3 years (<25) others too old (70+)
29 Case histories No cytology record in UK (excluding tests within 6 months of diagnosis) Woman aged 30 Symptomatic adenocarcinoma (stage IB1) presented with postcoital and intermenstrual bleeding TP cytology typical of AIS: reported?glandular neoplasia Trachelectomy: grade 2 adenocarcinoma, lymphovascular invasion but lymph nodes clear Screening history: No record in UK Previous negative smear in Sweden!
30 Case histories No cytology record in UK (excluding tests within 6 months of diagnosis) Woman aged 25 Symptomatic adenocarcinoma (stage IB1) presented with post-coital bleeding TP reported as?glandular neoplasia Died with lung metastases aged 28 Screening history: Was refused cytology test aged 19 and 21 (elsewhere in UK) because she was too young
31 Cytology >5 years before diagnosis: 21 of 133 (15.8%) 1 had previous low-grade cytology, not followed up 2 had previous CIN treatment, inadequate follow-up
32 Case histories Negative cytology >5 years before diagnosis) Woman aged 28 (medico-legal case) Routine cytology: severe dyskaryosis (HSIL favor CIN3) Screen-detected adenocarcinoma (stage IB1) treated by trachelectomy: completely excised, lymph nodes clear Screening history: Routine conventional smear aged 22, reported negative Moderate dyskaryosis on review (HSIL, favor CIN2) Defaulted from three reminders for screening aged 25
33 Reasons why cancers were not prevented Southampton (SSWH) and Guy s & St Thomas (GSTT)
34 Previous negative cytology 49/133 (37%) 27 negative only, 22 other factors Most frequent finding in interval cancers 11 (8%) had been screened as negative within 3.5 years with at least two tests within 10 years 16 had been screened as negative but less frequently than recommended ( years, only one previous test, long gaps before a recent test) 22 had other factors: also had low-grade repeats, delayed referral and/or CIN treatment) >50% confirmed as negative on review Others showed known pitfalls for false negatives
35 Some cancers are more difficult to prevent Austin and Zhao. Cytopathology 2012;23:6-12 Rapidly progressive cancers Cancers in young women Adenocarcinomas Cancers in older women (TZ in canal) (b) 26-year-old woman with small focus of CIN3 adjacent to poorly differentiated SqCC
36 Case histories Negative cytology years before diagnosis (interval cancer) Woman aged 57 Severe dyskaryosis on routine smear Screen-detected stage IA1 squamous cell carcinoma in background of CIN3 involving crypts on LLETZ; incompletely excised No residual CIN or cancer on hysterectomy Screening history: Five routine cytology tests every 3 years between age 42 and 54, all reported as negative; confirmed on review
37 Case histories Negative cytology years before diagnosis (interval cancer) Woman aged 35 Presented with intermenstrual bleeding; polypectomy Poorly differentiated adenosquamous carcinoma involving all margins lf the biopsy No residual carcinoma on hysterectomy; later recurrence and distant metastases; died Screening history: Four 3-yearly cytology tests every between age 22 and 31, all negative?glandular neoplasia (occasional cells) found on review of latest test 5 years before diagnosis
38 HSIL as small, pale or sparse cells (or all three) Hyperchromatic crowded groups (microbiopsies) overlooked Inadequate smears/lbc slides reported as negative HSIL misinterpreted as inflammatory HSIL favour CIN2 thought to be reactive metaplasia Known pitfalls at risk for being false negative
39 CGIN/AGC not recognised HSIL interpreted as reactive endocervical cells Known pitfalls at risk for being false negative
40 Previous repeats for LSIL/ASC/AGC HSIL misinterpreted as LSIL or ASC-US ASC-H or AGC not identified as such Follow-up sometimes not regarded as important Cancers rare in women followed up as recommended Referral of all LSIL and HPV triage for ASC-US should help
41 Case histories Repeat for low-grade years before diagnosis (interval cancer) Woman aged 28 Referred for mild dyskaryosis; previous borderline (ASC-US) LLETZ: screen-detected stage IA1 adenocarcinoma in a background of CIN1-2 Screening history: Referral smear reviewed: atypical glandular cells also seen
42 Slide review GSTT Neg. Inad. LSIL ASC-US ASC-H AGC HSIL+ Negative (n = 33) Inadequate (n = 4) LSIL/ASC (n = 9) Total (n = 46)
43 Cytology errors - How do EU guidelines help? Regular screening recommended (3-5 yearly) Rapid review of all negative or inadequate smears/slides recommended: internal QC Automated screening could be a powerful IQC tool as a method of rapid review (TP imager) Comparison of laboratory reporting rates may identify laboratories where HSIL might be missed or misinterpreted (EQA) Terminology - importance of ASC-H and AGC Training, update, continuing professional development, accreditation, proficiency testing (EQA), audit recommended for all laboratory staff
44 Reasons why cancers were not prevented Southampton and Guy s & St Thomas audits
45 Reasons for delay diagnosis/referral Referral advised >6 months before diagnosis Long colposcopy waiting lists (relatively short period of time in Southampton ) Interval of several months between referral, first biopsy and LLETZ (short period of time at GSTT) Women did not attend appointments (DNA) Women moved / travelled abroad / address not known (especially in London) Investigation / diagnosis delayed by pregnancy Referral for low-grade abnormalities not regarded as urgent or lesion not found at colposcopy Refused treatment (one for 7 years)
46 Previous treatment of CIN About 10% of cancers (both audits) were in women previously treated for CIN (usually CIN3, sometimes CIN2, occasionally CIN1) Most had incomplete excision, persistent abnormal cytology or biopsies after initial treatment or had defaulted from follow-up Rare in women treated for CGIN Small proportion of women treated for high-grade CIN (16 of 3,027 cases in nine years: 0.5%) More likely to have had initial treatment when aged over 35 years Low awareness of risk of recurrence: higher after incompletely excised or unconfirmed CIN3
47 Age of women at time of CIN treatment 100% 80% 60% 40% 65+ years years years years 20% 0% CIN2+ (n = 3,027) Cancer, previous CIN Rx (n = 16)
48 Case histories Previous treatment of CIN (interval cancer) Woman aged 40 (medico-legal case) Stage IIA invasive squamous cell carcinoma diagnosed on investigation of pelvic pain Mass in fornix thought to be endometriosis Biopsy: squamous cell carcinoma Screening history Three conventional follow-up smears reported as negative; disagreement about LUS vs. ASC-H on cytology of one Previous history not known by gynaecologist or cytopathologist: incompletely excised CIN3 (in crypts) Histology review of deeper levels showed focal invasion
49 Case histories Previous treatment of CIN (interval cancer) Woman aged 42 Severe dyskaryosis Colposcopy LBC: ASC-H Biopsy: high-grade CIN,?invasion LLETZ: focal koilocytosis ASC-US and ASC-H at colposcopy HC2-negative (x2) Hysterectomy for IMB: focal CIN3 IA1 squamous cell carcinoma and Screening history: Previous negative cytology since age 27
50 Invasive cancer audit shows where and why these guidelines matter Consistent terminology allows comparison of reporting rates and identification of ASC-H / AGC Rapid review, preview (or automated QC) allows potential false negatives to be avoided Recommendations for follow-up, investigation and counseling of women avoid default Accreditation supports monitoring outcome, audit, IQC and EQA of all aspects of screening Cancer audit identifies areas where procedures could be improved Screen-detected cancers should be put in context of CIN2+ detected during the same period of time
51 Cancers should be placed in the context of CIN2, CIN3 & CGIN (AIS) detected during the same period of time Number of cancers in each age band (GSTT ) Screen-detected (n = 65) Symptomatic (n = 68) CIN2 (1472) CIN3/CGIN (1555) Age band (years)
52 Thank you for listening!
EU guidelines for reporting gynaecological cytology
EU guidelines for reporting gynaecological cytology Amanda Herbert Guy s & St Thomas Foundation NHS Trust 5th EFCS Annual Tutorial, Trondheim, Norway 28 th May 1 st June 2012 EU guidelines aim to harmonize
More informationScottish Cervical Screening Programme. Colposcopy and Programme Management
Scottish Cervical Screening Programme Colposcopy and Programme Management Addendum to NHSCSP Publication No 20 Second Edition Exceptions Applicable in NHS Scotland April 2013 (Final Version 2.8 to incorporate
More informationLessons From Cases of Screened Women Who Developed Cervical Carcinoma
Lessons From Cases of Screened Women Who Developed Cervical Carcinoma R. Marshall Austin MD,PhD Magee-Womens Hospital of University of Pittsburgh Medical Center raustin@magee.edu Why Focus Study On Cases
More informationCuid d Fheidhmeannacht na Seirbhíse Sláinte. Part of the Health Service Executive. CS/PR/PM-20 Rev 2 ISBN Programme Report 2014/2015
Programme Report 2014/2015 Contents Summary points 2 Introduction to the statistics 2014/2015 3 Part 1 Cervical screening activity 3 Programme coverage 4 Laboratory turnaround time 7 Notification of results
More informationWIRRAL UNIVERSITY TEACHING HOSPITAL CYTOLOGY NHS CERVICAL SCREENING PROGRAMME INFORMATION PACK FOR SAMPLE TAKERS
Author J. Evans BMS 3 Authoriser A. Bamber Page 1 of 16 WIRRAL UNIVERSITY TEACHING HOSPITAL CYTOLOGY NHS CERVICAL SCREENING PROGRAMME INFORMATION PACK FOR SAMPLE TAKERS Author J. Evans BMS 3 Authoriser
More informationAn audit of liquid-based cervical cytology screening samples (ThinPrep and SurePath) reported as glandular neoplasia
DOI:10.1111/j.1365-2303.2009.00695.x An audit of liquid-based cervical cytology screening samples (ThinPrep and SurePath) reported as glandular neoplasia S. A. Thiryayi, J. Marshall and D. N. Rana Manchester
More informationEFCS Symposium. Is cervical cancer screening based on HPV testing with cytology triage as safe as perceived?
EFCS Symposium Is cervical cancer screening based on HPV testing with cytology triage as safe as perceived? Amanda Herbert Guy s & St Thomas NHS Foundation Trust Is cervical cancer screening based on HPV
More informationNorthern Ireland Cervical Screening Programme
Northern Ireland Cervical Screening Programme ANNUAL REPORT & STATISTICAL BULLETIN 2010-2011 1 Report produced by : Quality Assurance Reference Centre, PHA Date of Publication: September 2012 2 Contents
More informationVideo Workshop Cervical cancer screening as a multidisciplinary process
Video Workshop Cervical cancer screening as a multidisciplinary process Dr. Amanda Herbert (Guy s & St Thomas NHS Foundation Trust, London) Professor Jaroslava Duskova (Charles University, Prague, Czech
More informationManagement Algorithms for Abnormal Cervical Cytology and Colposcopy
Management Algorithms for Abnormal Cervical Cytology and Colposcopy Table of Contents Standard Colposcopic Definitions... 1 Guidelines for the Assessment of Abnormal Cervical Cytology... 2 Ia: Persistent
More informationCytology Update M Laing QEUH
Cytology Update M Laing QEUH Age change to 25 to 65 Age 25 to 50 Three yearly smear invitation Age 50 to 65 Five yearly smear invitation Women on non routine screening will be invited up to age 70 OUTCOME
More informationPOLICY FOR CLINICAL AUDIT OF NEW CASES OF INVASIVE CERVICAL CANCER AND DISCLOSURE OF RESULTS
POLICY FOR CLINICAL AUDIT OF NEW CASES OF INVASIVE CERVICAL CANCER AND DISCLOSURE OF RESULTS Reference Number Version: Status Author: Alison Cropper CL-CP/2009/010 V3 Final Job Title: Hospital Based Programme
More informationManagement of Abnormal Cervical Cytology and Histology
Management of Abnormal Cervical Cytology and Histology Assoc. Prof. Gökhan Tulunay Etlik Zübeyde Hanım Women s Diseases Teaching & Research Hospital Gynecologic Oncology Clinic Universally accepted guideline
More informationcle Modern management of abnormal cervical smear Tint Tint Wai and Dilip Patil BJMP 2008:1(2) 18-22
BJMP 2008:1(2) 18-22 Review Articl cle Modern management of abnormal cervical smear Tint Tint Wai and Dilip Patil Abbreviations BSCCP British Society of Colposcopy and Cervical Pathology CIN Cervical intraepithelial
More informationProposed new national cervical screening program. Dr Elizabeth Jackson Obstetrician Gynaecologist Cairns
Proposed new national cervical screening program Dr Elizabeth Jackson Obstetrician Gynaecologist Cairns www.drelizabethjackson.com Cervical cancer in Australia 12th most common cancer affecting Australian
More informationKing s Research Portal
King s Research Portal DOI: 10.1111/cyt.12259 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA):
More informationGUIDELINES FOR CERVICAL CYTOLOGY SPECIMENS CA1066 (V8) Approved by Guidelines Assessment Panel
NORFOLK & WAVENEY CELLULAR PATHOLOGY SERVICE GUIDELINES FOR CERVICAL CYTOLOGY SPECIMENS CA1066 (V8) DEPT. SOP NO.:C.SC.I.806b EDITION: 8 AUTHORISED BY: See table below AUTHOR: VIKI FREW DATE OF ISSUE:
More informationAppropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines
Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines Tim Kremer, MD Ralph Anderson, MD 1 Objectives Describe the natural history of HPV particularly as it relates
More informationThe Role of The Advanced Practitioner in Cytology
The Role of The Advanced Practitioner in Cytology Margaret Morgan Head of Service Cellular Pathology GSTS Pathology London Odense, Denmark 5 th March 2011 St Thomas Hospital London County Down Overview
More informationScreen-detected invasive cervical carcinoma and its clinical significance during the introduction of organized screening
DOI: 10.1111/j.1471-0528.2008.01989.x www.blackwellpublishing.com/bjog Epidemiology Screen-detected invasive cervical carcinoma and its clinical significance during the introduction of organized screening
More informationWorkshop for O& G trainees and paramedics 17 Dec 2011 Cytological Interpretation
Workshop for O& G trainees and paramedics 17 Dec 2011 Cytological Interpretation May Yu Director of Cytology Laboratory Service Department of Anatomical & Cellular Pathology Prince of Wales Hospital Cervical
More informationObjectives. Atypical Glandular Cells. Atypical Endocervical Cells. Reactive Endocervical Cells
2013 California Society of Pathologists 66 th Annual Meeting San Francisco, CA Atypical Glandular Cells to Early Invasive Adenocarcinoma: Cervical Cytology and Histology Christina S. Kong, MD Associate
More informationThe routine use of ZedScan within one colposcopy service in England. MC Macdonald, R Lyon, JE Palmer, JA Tidy
The routine use of ZedScan within one colposcopy service in England MC Macdonald, R Lyon, JE Palmer, JA Tidy Introduction Colposcopic impression alone has been shown to be subjective with variable rates
More informationNatural History of HPV Infections 15/06/2015. Squamous cell carcinoma Adenocarcinoma
14,670 5796 United States/ Canada 17,165 8124 Central America 48,328 21,402 South America 59,929 29,814 Europe 78,896 61,670 Africa 157,759 86,708 Southcentral Asia 61,132 31,314 Eastern Asia 42,538 22,594
More informationNHS Cervical Screening Programme in Kingston and Richmond ANNUAL REPORT
Kingston Borough Team Richmond and Twickenham Borough Team 1. Introduction NHS Cervical Screening Programme in Kingston and Richmond ANNUAL REPORT 2010-12 All women between the ages of 25 and 64 are eligible
More informationHPV-Negative Results in Women Developing Cervical Cancer: Implications for Cervical Screening Options
HPV-Negative Results in Women Developing Cervical Cancer: Implications for Cervical Screening Options R. Marshall Austin MD,PhD Magee-Womens Hospital of University of Pittsburgh Medical Center (UPMC) (raustin@magee.edu)
More informationNorthern Ireland cervical screening programme. Information for primary care and smear takers
Northern Ireland cervical screening programme Information for primary care and smear takers From January 2011, the Northern Ireland cervical screening programme will no longer invite women aged under 25
More informationCPC on Cervical Pathology
CPC on Cervical Pathology Dr. W.K. Ng Senior Medical Officer Department of Clinical Pathology Pamela Youde Nethersole Eastern Hospital Cervical Smear: High Grade SIL (CIN III) Cervical Smear: High Grade
More informationCervical Cancer Screening. David Quinlan December 2013
Cervical Cancer Screening David Quinlan December 2013 Cervix Cervical Cancer Screening Modest variation provincially WHO and UK begin at 25 stop at 60 Finland begin at 30 stop at 60 Rationale for
More informationDepartment of Health Standard for the Cervical Cancer Screening Program. Approval Date: 08 May 2018 Effective Date: 13 May 2018
Document Title: Department of Health Standard for the Cervical Cancer Screening Program Document Ref. Number: DOH/CCSC/SD/1.0 Version: 1.0 Approval Date: 08 May 2018 Effective Date: 13 May 2018 Last Reviewed:
More informationManchester Cytology Centre APRIL 2012
Directorate of Laboratory Medicine Manchester Cytology Centre NHS Cervical Screening Programme INFORMATION PACK FOR SAMPLE TAKERS APRIL 2012 April 2012 [CYT GEN 029 Version 004] 1 SUMMARY OF CHANGES Page
More informationColposcopy. Attila L Major, MD, PhD
Colposcopy Attila L Major, MD, PhD Histology Colposcopy Cytology It has been estimated that annual Pap smear testing reduces a woman s chance of dying of cervical cancer from 4 in 1000 to about 5 in 10,000
More informationPlus ça change. CWE Redman Colposcopy Symposium, ECC 2016
Plus ça change. CWE Redman Colposcopy Symposium, ECC 2016 UHNM What we know HPV primary screening coming More sensitive: more HSIL detected Increase in workload Longer consultations More anxiety HPV Primary
More informationASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests
ASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests www.treatmentok.com Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Ann Arbor, Michigan Disclosures
More informationNHSCSP proposals for cervical screening intervals. Comments and recommendations of Council of the British Society for Clinical Cytology
NHSCSP proposals for cervical screening intervals Comments and recommendations of Council of the British Society for Clinical Cytology The following paper is written on behalf of BSCC Council to express
More informationEuropean Union survey on organization and quality control of cervical cancer screening and HPV vaccination programs
European Union survey on organization and quality control of cervical cancer screening and HPV vaccination programs Introduction to the Survey The purpose of this project is to collect information regarding
More informationCervical Cancer Screening Update. Melissa Hartman, DO Women s Health
Cervical Cancer Screening Update Melissa Hartman, DO Women s Health Previous Cervical Cancer Screening Organization Recommendation ACS (2011) ACP (2008) NCI (2003) Age 21 or 3 years after first intercourse
More informationMaking Sense of Cervical Cancer Screening
Making Sense of Cervical Cancer Screening New Guidelines published November 2012 Tammie Koehler DO, FACOG The incidence of cervical cancer in the US has decreased more than 50% in the past 30 years because
More informationGlandular lesions in cervical cytology. Margareta Strojan Fležar Institute of Pathology Faculty of Medicine University of Ljubljana Slovenia
Glandular lesions in cervical cytology Margareta Strojan Fležar Institute of Pathology Faculty of Medicine University of Ljubljana Slovenia 2nd PANNONIA CONGRESS OF PATHOLOGY, SIÓFOK, HUNGARY, 17-19 MAY
More informationA clinical review of borderline glandular cells reported on liquid-based cervical cytology
DOI: 10.1111/j.1471-0528.2009.02477.x www.bjog.org Gynaecological oncology A clinical review of borderline glandular cells reported on liquid-based cervical cytology A Patel, a N Thampy, b D Hemming, b
More informationFaculty Pap Smear Guidelines: Family Planning Update 2008 Part Two
Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two Seshu P. Sarma, MD, FAAP Emory University Regional Training Center Atlanta, Georgia Produced by the Alabama Department of Public Health
More informationCervical Skills. Dr Margaret Laing Queen Elizabeth University Hospital
Cervical Skills Dr Margaret Laing Queen Elizabeth University Hospital What is screening? Screening is a test offered to an apparently well person with the possibility of detecting a serious disease before
More informationCERVICAL SCREENING WALES CERVICAL SCREENING PROGRAMME, WALES: 2001/02
CERVICAL SCREENING WALES INFORMATION TEAM STATISTICAL REPORT CERVICAL SCREENING PROGRAMME, WALES: 2001/02 For more information about this report contact: Helen Beer, Information Analyst / Manager, Screening
More informationHKCOG GUIDELINES NUMBER 3 (revised November 2002) published by The Hong Kong College of Obstetricians and Gynaecologists
HKCOG Guidelines Guidelines on the Management of An Abnormal Cervical Smear Number 3 revised November 2002 published by The Hong Kong College of Obstetricians and Gynaecologists A Foundation College of
More informationScreening for the Precursors of Cervical Cancer in the Era of HPV Vaccination. Dr Stella Heley Senior Liaison Physician Victorian Cytology Service
Screening for the Precursors of Cervical Cancer in the Era of HPV Vaccination Dr Stella Heley Senior Liaison Physician Victorian Cytology Service Victorian Cytology Service Dr Stella Heley Dr Siobhan Bourke
More informationUnderstanding Your Pap Test Results
Understanding Your Pap Test Results Most laboratories in the United States use a standard set of terms called the Bethesda System to report pap test results. Normal: Pap samples that have no cell abnormalities
More informationGlandular Atypia In Cervical Smear: Cytohistologic And Clinical Correlation. K Elsapagh, S Swain, S Ghosh, H Dunsmore, K McMullen, J Steven, K Morton
ISPUB.COM The Internet Journal of Gynecology and Obstetrics Volume 5 Number 2 Glandular Atypia In Cervical Smear: Cytohistologic And Clinical Correlation K Elsapagh, S Swain, S Ghosh, H Dunsmore, K McMullen,
More informationCervicovaginal Cytology: Normal and Abnormal Cells and Adequacy of Specimens
Cervicovaginal Cytology: Normal and Abnormal Cells and Adequacy of Specimens 3 Christine Bergeron, MD, PhD Introduction Carcinoma of the cervix is a slow growing cancer, which is preceded by precancerous
More informationBC Cancer Cervix Screening 2015 Program Results. February 2018
BC Cancer Cervix Screening 2015 Program Results BC Cancer Cervix Screening 2015 Program Results 2 Table of Contents BC Cancer Cervix Screening 2015 Program Results... 1 Table of Contents... 2 Program Overview...
More information!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$
!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$ Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
More information6 th EFC Satellite meeting, Saturday 1 st December 2018
6 th EFC Satellite meeting, Saturday 1 st December 2018 Introduction Pekka Nieminen President-elect of the European Federation for Colposcopy, Department of Obstetrics and Gynaecology, Helsinki University
More informationCERVICAL INTRAEPITHELIAL NEOPLASIA (CIN)
CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) The cervix constitutes the lower third of the uterus. It is in two parts, the endocervix and the ectocervix. Ectocervix is covered with squamous epithelium. Endocervix
More informationNATIONAL CERVICAL CANCER SCREENING PROGRAMME Monitor 2017
a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a NATIONAL CERVICAL CANCER SCREENING PROGRAMME Monitor
More informationUpdated ASCCP Consensus Guidelines For Managing Diagnosed Cervical Cancer Precursors Michael A. Gold, M.D.
Updated ASCCP Consensus Guidelines For Managing Diagnosed Cervical Cancer Precursors Michael A. Gold, M.D. 27 May, 2014 London, England Faculty Disclosure X No, nothing to disclose Yes, please specify
More informationNHSCSP AUDIT OF INVASIVE CERVICAL CANCER: NATIONAL REPORT
NHSCSP AUDIT OF INVASIVE CERVICAL CANCER: NATIONAL REPORT 2009-2012 NHSCSP audit of invasive cervical cancer: national report 2009-2012 i Lead Authors Professor Peter Sasieni Professor of Biostatistics
More informationClinical Guidance: Recommended Best Practices for Delivery of Colposcopy Services in Ontario Best Practice Pathway Summary
Clinical Guidance: Recommended Best Practices for Delivery of Colposcopy Services in Ontario Best Practice Pathway Summary Glossary of Terms Colposcopy is the examination of the cervix, vagina and, in
More informationPreventing Cervical Cancer 2018 WHAT THIS WILL MEAN FOR PRIMARY CARE
Preventing Cervical Cancer 2018 WHAT THIS WILL MEAN FOR PRIMARY CARE DR GARY FENTIMAN, CLINICAL LEADER COLPOSCOPY, N C S P TAKE-HOME LESSONS Vaccination is Primary Prevention for Cervical Cancer Women
More informationStudy Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationEfficacy of cervical intrarepithelial neoplasia (CIN)
The Ulster Medical Journal, Volume 72, No. 1, pp. 10-15, May 2003. Efficacy of cervical intrarepithelial neoplasia (CIN) treatment by cold coagulation A Zawislak, J H Price, H R McClelland, R G N Storey,
More informationObjectives. I have no financial interests in any product I will discuss today. Cervical Cancer Screening Guidelines: Updates and Controversies
Cervical Cancer Screening Guidelines: Updates and Controversies I have no financial interests in any product I will discuss today. Jody Steinauer, MD, MAS University of California, San Francisco Objectives
More informationCervical Precancer: Evaluation and Management
TAJ June 2002; Volume 15 Number 1 ISSN 1019-8555 The Journal of Teachers Association RMC, Rajshahi Review fam Cervical Precancer: Evaluation and Management SM Khodeza Nahar Begum 1 Abstract Carcinoma of
More informationCryotherapy has No Place in Colposcopy Practice
Cryotherapy has No Place in Colposcopy Practice No financial disclosures No conflicts of interest ? Precision? Personalized Medicine? Best Evidence Based Practice Prinicipals of Surgical Management CIN1
More informationHistopathology: Cervical HPV and neoplasia
Histopathology: Cervical HPV and neoplasia These presentations are to help you identify basic histopathological features. They do not contain the additional factual information that you need to learn about
More informationChapter 10: Pap Test Results
Chapter 10: Pap Test Results On completion of this section, the learner will be able to: 1. Identify how Pap test results are interpreted and the reasons for normal and abnormal results. 2. Describe the
More informationBRITISH COLUMBIA S CERVICAL CANCER SCREENING PROGRAM
BRITISH COLUMBIA S CERVICAL CANCER SCREENING PROGRAM DATE: NOVEMBER 19, 2016 PRESENTER: DR. DIRK VAN NIEKERK 1 Conflict of Interest Disclosure Nothing to disclose 2 ..in the beginning of the malady it
More informationThe society for lower genital tract disorders since 1964.
The society for lower genital tract disorders since 1964. Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
More informationNational Cervical Screening Program MBS Item Descriptors
National Cervical Screening Program MBS Item Descriptors Item Item descriptor 73070 A test, including partial genotyping, for oncogenic human papillomavirus that may be associated with cervical pre-cancer
More informationManitoba Cervical Cancer Screening Program. Operations & Statistical Report and 2006
anitoba Cervical Cancer Screening Program Operations & Statistical Report 2005 and 2006 1 MCCSP 2005-2006 Report ANITOBA CERVICAL CANCER SCREENING PROGRAM 2005 and 2006 Operations & Statistical Report
More informationZedScan delivers improvements in clinical performance and more efficient patient management at Sheffield Teaching Hospitals NHS Foundation Trust
ZedScan Case Study NHS Hospital, UK. ZedScan delivers improvements in clinical performance and more efficient patient management at Sheffield Teaching Hospitals NHS Foundation Trust Increased detection
More informationLLETZ (Large Loop Excision of the Transformation Zone) Fragmentation: Impact on Margin Assessment and Cervical Biopsy-LLETZ Correlation
LLETZ (Large Loop Excision of the Transformation Zone) Fragmentation: Impact on Margin Assessment and Cervical Biopsy-LLETZ Correlation Bridget Melley BSc. (Hons.) in Medical Science Galway-Mayo Institute
More informationCervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013
Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines General Principles: Since its introduction in 1943, Papanicolaou (Pap) smear is widely
More informationGynaecological Pathology Reporting Cervical Pathology Dr Raji Ganesan Birmingham
Gynaecological Pathology Reporting Cervical Pathology Dr Raji Ganesan Birmingham Format Introduction Cervical biopsy Difficulties in diagnosis of CIN p16 Cervical loop Squamous carcinoma diagnosing and
More informationThe role of human papillomavirus testing in the management of women with low-grade abnormalities: multicentre randomised controlled trial
DOI: 10.1111/j.1471-0528.2010.02519.x www.bjog.org Epidemiology The role of human papillomavirus testing in the management of women with low-grade abnormalities: multicentre randomised controlled trial
More informationPRE TEST CERVICAL SCREENING MANAGEMENT COLPOSCOPY PATHOLOGIC DIAGNOSIS AND TREATMENT
PRE TEST CERVICAL SCREENING MANAGEMENT COLPOSCOPY PATHOLOGIC DIAGNOSIS AND TREATMENT QUESTION #1 WHICH OF THE FOLLOWING IS NOT A RISK FACTOR FOR CERVICAL CANCER? A. HIGH RISK HPV B. CIGARETTE SMOKING C.
More informationKC53/61/65 Statistical Report Adroddiad Ystadegol 2012/13 Prepared by Cervical Screening Wales
KC53/61/65 Statistical Report Adroddiad Ystadegol 2012/13 Prepared by Cervical Screening Wales CERVICAL SCREENING WALES STATISTICAL REPORT CERVICAL SCREENING PROGRAMME, WALES: 2012/2013 For more information
More informationPrimary High Risk HPV Testing with Cytology Triage
Primary High Risk HPV Testing with Cytology Triage NHS Cervical Screening Programme Public Health England leads the NHS Screening Programmes Human papillomavirus (HPV) High risk (HR) HPV is associated
More informationThe new Cervical Screening Test for Australian women: Louise Farrell
The new Cervical Screening Test for Australian women: Louise Farrell Outline and explain the changes to the National Cervical Screening Program due to commence in Dec 2017 LEARNING OBJECTIVES FOR TODAY
More information1 September 2011 to 31 August Programme Report
1 September 2011 to 31 August 2012 Programme Report CervicalCheck Charter Screening commitment: CervicalCheck The National Cervical Screening Programme offers a free complete quality assured programme
More informationQA and Quality Indicators for Cervical Cancer Screening Programs. Guglielmo Ronco MD Senior Epidemiologist CPO Piemonte Turin, Italy
QA and Quality Indicators for Cervical Cancer Screening Programs Guglielmo Ronco MD Senior Epidemiologist CPO Piemonte Turin, Italy Disclosures No financial relationships or conflict of interest to disclose
More informationEradicating Mortality from Cervical Cancer
Eradicating Mortality from Cervical Cancer Michelle Berlin, MD, MPH Vice Chair, Obstetrics & Gynecology Associate Director, Center for Women s Health June 2, 2009 Overview Prevention Human Papilloma Virus
More informationBiomed Environ Sci, 2015; 28(1): 80-84
80 Biomed Environ Sci, 2015; 28(1): 80-84 Letter to the Editor Assessing the Effectiveness of a Cervical Cancer Screening Program in a Hospital-based Study* YANG Yi1, LANG Jing He1, WANG You Fang1, CHENG
More informationCervical Cancer 4/27/2016
Guidelines for Cervical Cancer Screening and Prevention Management of Abnormal Results Kathy A. King, MD Assistant Professor of OB/GYN Medical College of Wisconsin May 6, 2016 Cervical Cancer In US about
More informationCervical Screening for Dysplasia and Cancer in Patients with HIV
Cervical Screening for Dysplasia and Cancer in Patients with HIV Adult Clinical Guideline from the New York State Department of Health AIDS Institute w w w.hivg uidelines.org Purpose of the Guideline Increase
More informationComparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer
BJOG: an International Journal of Obstetrics and Gynaecology August 2004, Vol. 111, pp. 842 848 DOI: 1 0. 1111/j.1471-0528.2004.00210.x Comparison of HPV test versus conventional and automation-assisted
More informationStreamlining Protocols-From Strategy to Implementation. Doreen Ramogola-Masire Botswana UPenn Partnership June 2014
Streamlining Protocols-From Strategy to Implementation Doreen Ramogola-Masire Botswana UPenn Partnership 18-20 June 2014 Botswana-UPenn Partnership Partnership between Government of Botswana, University
More informationName of External Assessment Group (EAG) and project leads
Title of the project Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: a systematic review and economic evaluation Name of External Assessment Group (EAG) and project leads
More informationCase Based Problems. Recommended Guidelines. Workshop: Case Management of Abnormal Pap Smears and Colposcopies. Disclosure
Disclosure Workshop: Case Management of Abnormal Pap Smears and Colposcopies Rebecca Jackson, MD Associate Professor Obstetrics, Gynecology & Reproductive Sciences and Epidemiology & Biostatistics This
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Screening Update and Implications for Annual Exams George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Prevention: 2012 and Beyond George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics University of California,
More informationI have no financial interests to disclose.
Workshop: Case Management of Abnormal Pap Smears and Colposcopies Rebecca Jackson, MD Professor Obstetrics, Gynecology & Reproductive Sciences and Epidemiology & Biostatistics I have no financial interests
More information07 August Dear Colleague,
07 August 2018 Dear Colleague, Further to our letter dated 9 May 2018, we are writing today to all healthcare professionals registered with CervicalCheck with updated advice and information regarding CervicalCheck.
More informationCervical cancer presentation
Carcinoma of the cervix: Carcinoma of the cervix is the second commonest cancer among women worldwide, with only breast cancer occurring more commonly. Worldwide, cervical cancer accounts for about 500,000
More informationThe comparative diagnostic accuracy of conventional and liquid-based cytology in a colposcopic setting
BJOG: an International Journal of Obstetrics and Gynaecology November 2005, Vol. 112, pp. 1542 1546 DOI: 10.1111/j.1471-0528.2005.00699.x The comparative diagnostic accuracy of conventional and liquid-based
More informationHPV: cytology and molecular testing
HPV: cytology and molecular testing Human Papillomavirus and how we test for it at Medlab Central Palmerston North for Cervical Cancer prevention and management. Developed by Reem Mustafa Cytology and
More informationManagament of Abnormal Cervical Cytology and Histology
Managament of Abnormal Cervical Cytology and Histology Ali Ayhan, M.D Başkent University Faculty of Medicine Department of Gynecology and Obstetrics Division of Gynecologic Oncology Abnormal Cytologic
More informationProposed New Guidelines for the Management of Women with Abnormal Cervical Smears DRAFT FOR COMMENT
Proposed New Guidelines for the Management of Women with Abnormal Cervical Smears DRAFT FOR COMMENT National Cervical Screening Programme National Screening Unit Ministry of Health October 2006 Table of
More informationGLANDULAR LESIONS PITFALLS IN MANAGEMENT. Dr Li Wai Hon HKSCCP The 15 th Anniversary Symposium 10 December 2016
GLANDULAR LESIONS PITFALLS IN MANAGEMENT Dr Li Wai Hon HKSCCP The 15 th Anniversary Symposium 10 December 2016 Introduction Cervical glandular lesions are much less common than squamous lesion Incidence
More informationThe Renewed National Cervical Screening Program:
The Renewed National Cervical Screening Program: Key information for Health Professionals Contents: Overview: National Cervical Screening Program... 2 Background: HPV and cervical cancer... 3 HPV testing
More informationPreventing cervical cancer Australia. The Renewed National Cervical Screening Program 2019 Common Questions and Cases
The Renewed National Cervical Screening Program 2019 Common Questions and Cases Preventing cervical cancer Australia - National HPV vaccination program - The National cervical screening program Annabelle
More informationChapter 8 Adenocarcinoma
Page 80 Chapter 8 Adenocarcinoma Overview In Japan, the proportion of squamous cell carcinoma among all cervical cancers has been declining every year. In a recent survey, non-squamous cell carcinoma accounted
More information